Furthermore, we test oncogene-targeted TKIs with EGFR, HER2, and BRAF inhibitors using EGFR-mutant (EGFR+) NSCLC, HER2-amplified (HER2+) breast cancer (BC), and BRAF-mutant (BRAF+) melanoma cells10. This evidence concerns the gene ERBB2 and melanoma.